S1 tops the poll as best adjuvant treatment for pancreatic cancer

  • Kamarajah SK & al.
  • HPB (Oxford)
  • 29 Dec 2019

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A new network meta-analysis demonstrates that chemotherapy with S1 or FOLFRINOX (mFFX) is superior to gemcitabine/capecitabine (GemCap) for adjuvant treatment for pancreatic ductal adenocarcinoma.

A systematic review was conducted using MEDLINE, EMBASE, Cochrane Central and the American Society of Clinical Oncology abstracts to identify phase 3 randomised controlled trials that examined adjuvant systemic therapy in resected pancreatic cancer that were published up to 9 May 2019.

Twelve trials involving 4947 patients and nine different regimens (5-flourouracil/folinic acid [5-FU/FA], gemcitabine, gemcitabine/erlotinib, GemCap, mFFX, S1, chemoradiotherapy (CRT) and CRT with either 5-FU or gemcitabine) were identified.

S1 ranked best for overall (OS) and disease-free survival (DFS), followed by mFFX.

There was no significant difference between S1 and mFFX for OS (mean difference: 1.6 months; P=.8), but S1 had significantly longer DFS than mFFX (mean difference: 2.8 months; P<.001 s1 also ranked best for lowest overall and haematological grade toxicities.>

The authors say the findings that chemotherapy with S1 or mFFX improves survival after surgical resection and should be considered reasonable standard treatment options in the adjuvant setting.